MedTrace Logo

FLT-PET Imaging of Brain Tumors in Children

NCT01244737 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-07-11

Study results available
· View outcomes & findings →

Summary

Brain tumors are the leading cause of death from solid tumors in children. Tumor imaging is important in the management of these tumors, but current imaging methods have limitations in providing the necessary information for optimal treatment of these patients. The goal of this study is to evaluate the potential utility of positron emission tomography (PET) with 3'-deoxy-3'-\[F-18\] fluorothymidine (18F-FLT) in the medical management of brain tumors in children. Funding source - FDA Office of Orphan Product Development (OOPD)

Conditions

  • Brain Neoplasms

Interventions

DRUG

[18F] FLT

\[18F\] FLT, intravenous, at a dose of 0.15 mCi/kg once before a PET scan

Sponsors & Collaborators

Principal Investigators

  • Frederick D Grant, MD · Children's Hospital, Boston, Harvard Medical School

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2023-02-05
Completion
2023-02-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01244737 on ClinicalTrials.gov